Publications
- Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II2013 | First Faculty of Medicine
- Research Report University Hospital clinical trial AZA-MDS-003Publication without faculty affiliation
- De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors2024 | Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib2024 | First Faculty of Medicine
- Immune deregulation in myelodysplastic syndromes - the role of cytokines and soluble adhesion molecules. A pilot study2023 | Faculty of Medicine in Hradec Králové
- Treatment of polycythemia vera with ropeginterferon alfa‑2b in a young woman with a successful pregnancy – case report2023 | Faculty of Medicine in Hradec Králové
- Karotidynie (TIPIC syndrom) u pacientky s paroxysmální noční hemoglobinurií2022 | Faculty of Medicine in Hradec Králové
- MonoMAC syndrome with GATA2 novel mutation: A case report2022 | Faculty of Medicine in Hradec Králové
- Treatment strategies for myelodysplastic syndrome in 20212021 | Faculty of Medicine in Hradec Králové
- Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome2021 | Faculty of Medicine in Hradec Králové
Loading network view...